Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
Kristian Thorlund, Kyle Sheldrick, Gideon Meyerowitz-Katz, Sonal Singh, Andrew Hill
The American Journal of Tropical Medicine and Hygiene, doi:10.4269/ajtmh.21-1339
Oral therapies for the early treatment of COVID-19 may prevent disease progression and health system overcrowding. A new oral therapeutic named molnupiravir has been promoted as providing an approximately 50% reduction in death or the need for hospitalization. The clinical trial evaluating this drug was stopped early at the recommendation of the Data Safety and Monitoring Board after approximately 50% of the sample had been recruited. At the point of discontinuing the trial, approximately 90% of the planned sample had been recruited and had available follow-up data accessible. We discuss issues about the study conduct, analysis, and interpretation, including 1) the authors and sponsors presented the interim analysis as the primary analysis; 2) communication between sponsors and the Data Safety and Monitoring Board was insufficient; 3) the treatment effects reverse when examining only the post-interim analysis population, and are substantially attenuated when examining the full data; 4) the choice of primary analysis is incorrect; 5) analysis of lost-to-follow-up patients favors the study drug; and 6) other known molnupiravir trials were not presented in the primary study findings. As a result of methodological and statistical concerns, it seems that external trials, separate from those supported by the sponsoring company, are required to determine the utility of this drug.
References
Arribas, on behalf of the MOVe-IN study group, 2022. Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19, NEJM Evid
Balakrishnan, Hetero Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India
Bassler, Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis, JAMA
Bernal, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Curtis, Hazuda, Kb, Molnupiravir. US FDA Antimicrobial Drugs Advisory Committee Meeting
Kumarasamy, Saha, Jindal, Singh, Rodduturi et al., Phase III trial of molnupiravir in adults with mild SARS-COV2 infection in India (Abstract #101
Lakens, P-hacking and Optional Stopping Have Been Judged Violations of Scientific Integrity
Merck, Merck Statement on Clinical Data for Molnupiravir Generated by Hetero in India
News, Merck and Ridgeback's Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study
Park, Decloedt, Rayner, Cotton, Mills, Clinical trials of disease stages in COVID 19: complicated and often misinterpreted, Lancet Glob Health
Perappadan, Molnupiravir Kept Out of Revised Clinical Guidelines for Management of Adult COVID-19 Patients
Siemieniuk, Drug treatments for COVID-19: living systematic review and network meta-analysis, BMJ
Singh, Mitra, Arora, Two Indian drugmakers to end trials of generic Merck pill for moderate COVID-19
Spencer, Parodi, France Cancels Order for Merck's COVID-19 Antiviral Drug
Tandon, Molnupiravir Harms Far Outweigh Claimed Benefits: ICMR's Second Warning in a Week
The, Group, Patient-Reported Outcomes: 17b: Binary Outcomes
DOI record:
{
"DOI": "10.4269/ajtmh.21-1339",
"ISSN": [
"0002-9637",
"1476-1645"
],
"URL": "http://dx.doi.org/10.4269/ajtmh.21-1339",
"abstract": "<jats:p>Oral therapies for the early treatment of COVID-19 may prevent disease progression and health system overcrowding. A new oral therapeutic named molnupiravir has been promoted as providing an approximately 50% reduction in death or the need for hospitalization. The clinical trial evaluating this drug was stopped early at the recommendation of the Data Safety and Monitoring Board after approximately 50% of the sample had been recruited. At the point of discontinuing the trial, approximately 90% of the planned sample had been recruited and had available follow-up data accessible. We discuss issues about the study conduct, analysis, and interpretation, including 1) the authors and sponsors presented the interim analysis as the primary analysis; 2) communication between sponsors and the Data Safety and Monitoring Board was insufficient; 3) the treatment effects reverse when examining only the post-interim analysis population, and are substantially attenuated when examining the full data; 4) the choice of primary analysis is incorrect; 5) analysis of lost-to-follow-up patients favors the study drug; and 6) other known molnupiravir trials were not presented in the primary study findings. As a result of methodological and statistical concerns, it seems that external trials, separate from those supported by the sponsoring company, are required to determine the utility of this drug.</jats:p>",
"author": [
{
"affiliation": [
{
"name": "1Department of Health Research Methods, Evidence & Impact, McMaster University, Hamilton, Ontario, Canada;"
}
],
"family": "Thorlund",
"given": "Kristian",
"sequence": "first"
},
{
"affiliation": [
{
"name": "2University of New South Wales, Kensington, Australia;"
}
],
"family": "Sheldrick",
"given": "Kyle",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "3School of Health and Society, University of Wollongong, New South Wales, Australia;"
}
],
"family": "Meyerowitz-Katz",
"given": "Gideon",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "4Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, Massachusetts;"
}
],
"family": "Singh",
"given": "Sonal",
"sequence": "additional"
},
{
"affiliation": [
{
"name": "5Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom"
}
],
"family": "Hill",
"given": "Andrew",
"sequence": "additional"
}
],
"container-title": [
"The American Journal of Tropical Medicine and Hygiene"
],
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2022,
3,
11
]
],
"date-time": "2022-03-11T13:22:38Z",
"timestamp": 1647004958000
},
"deposited": {
"date-parts": [
[
2022,
3,
11
]
],
"date-time": "2022-03-11T13:22:38Z",
"timestamp": 1647004958000
},
"indexed": {
"date-parts": [
[
2022,
3,
11
]
],
"date-time": "2022-03-11T13:41:57Z",
"timestamp": 1647006117889
},
"is-referenced-by-count": 0,
"issn-type": [
{
"type": "print",
"value": "0002-9637"
},
{
"type": "electronic",
"value": "1476-1645"
}
],
"issued": {
"date-parts": [
[
2022,
3,
11
]
]
},
"license": [
{
"URL": "https://creativecommons.org/licenses/by/4.0/",
"content-version": "unspecified",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
3,
11
]
],
"date-time": "2022-03-11T00:00:00Z",
"timestamp": 1646956800000
}
}
],
"link": [
{
"URL": "https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-ajtmh.21-1339/article-10.4269-ajtmh.21-1339.xml",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://www.ajtmh.org/downloadpdf/journals/tpmd/aop/article-10.4269-ajtmh.21-1339/article-10.4269-ajtmh.21-1339.xml",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "2795",
"original-title": [],
"prefix": "10.4269",
"published": {
"date-parts": [
[
2022,
3,
11
]
]
},
"published-print": {
"date-parts": [
[
2022,
3,
11
]
]
},
"publisher": "American Society of Tropical Medicine and Hygiene",
"reference-count": 0,
"references-count": 0,
"relation": {},
"resource": {
"primary": {
"URL": "https://www.ajtmh.org/view/journals/tpmd/aop/article-10.4269-ajtmh.21-1339/article-10.4269-ajtmh.21-1339.xml"
}
},
"score": 1,
"short-container-title": [],
"short-title": [],
"source": "Crossref",
"subject": [
"Virology",
"Infectious Diseases",
"Parasitology"
],
"subtitle": [],
"title": [
"Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial"
],
"type": "journal-article"
}
